Tumour cell and stromal features in metastatic and non-metastatic non-small cell lung carcinomas

Aims:  Tumour cell behaviour depends on the interactions between nuclear genetic changes in the malignant cells and a stroma favourable for growth, invasion and metastasis. To evaluate such interactions, we studied the relationship between tumour cell and stromal features for proliferative factors,...

Full description

Saved in:
Bibliographic Details
Published in:Histopathology Vol. 43; no. 5; pp. 427 - 443
Main Authors: Minamoto, H, Antonângelo, L, Da Silva, A G P, Gallo, C P, De Andrade e Silva, F B, Fenezelian, S, Rodrigues, O R, Jatene, F, Saldiva, P, Capelozzi, V L
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Science Ltd 01-11-2003
Blackwell
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims:  Tumour cell behaviour depends on the interactions between nuclear genetic changes in the malignant cells and a stroma favourable for growth, invasion and metastasis. To evaluate such interactions, we studied the relationship between tumour cell and stromal features for proliferative factors, p53, microvessel density and metalloproteinases, controlled for the extent of the primary lesion (T1 to T4), in early (non‐metastatic) and late (metastatic) non‐small cell lung carcinomas (NSCLC). Methods and results:  Variables were examined for differences and correlations in the frequency of p53, AgNOR, CD34 and MMP‐9 expression in primary lesions and metastases of NSCLC using a general linear model. The patients included 58 males and 22 females (mean age 62 ± 9 years) with 19 T1 (23.8%), 40 T2 (50.0%), 14 T3 (17.5%) and seven T4 (8.8%). In late disease, AgNOR and p53 were statistically related to the extent of the primary lesion, whereas in early disease AgNOR tended to be increased in tumours without metastasis, while p53 expression tended to decrease progressively in tumours with metastasis. Microvessel density in late disease was of no statistical significance, whereas in early disease strong CD34 expression was seen in tumours with metastasis, being at its maximum in T3 primary lesions. The best marker for the extent of the lesion and its progression was MMP‐9, with greater expression by tumours with metastasis than those without. Conclusions:  Different tumour cell and stromal interactions control metastasis and therefore the biological risk of NSCLC. A panel of molecular markers, such as p53, MMP‐9 and CD34 could help to identify subgroups of patients that could benefit from adjuvant therapy.
Bibliography:ArticleID:HIS1704
istex:77DC7521880A60AC26A63EE21F7EBE0437C06877
ark:/67375/WNG-S3468CGT-J
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0309-0167
1365-2559
DOI:10.1046/j.1365-2559.2003.01704.x